![]() Endo believes that presenting these non-GAAP measures provides useful information about Endo's performance across reporting periods on a consistent basis by excluding cer tain items, which may be favorable or unfavorable, pursuant to certain specified procedures. Endo utilizes these financial measures because (i) they are used by Endo, along with financial measures inĪccordance with GAAP, to evaluate Endo's operating performance (ii) Endo believes that they will be used by certain investor s to measure Endo's operating results (iii) the Compensation & Human Capital Committee of Endo's Board of Directors uses adjusted diluted net income per share from continuing operations and adjusted EBITDA, or measures derived from such, in assessing the performance and compensation of substantially all of Endo's employees, including executive officers and (iv) Endo's leverage ratio, as defined by Endo's credit agreement, is calculated based on non -GAAP financial measures. This presentation may refer to non-GAAP financial measures, including, among others, adjusted diluted net income per share from continuing operations, adjusted EBITDA, adjusted income from continuing operations, adjusted gross margin, adjusted operating expenses, adjusted effective ta x rate, adjusted revenue and adjusted weighted average diluted shares that are not prepared in accordance with accounting principles generally accepted in the Unit ed States and that may be different from non-GAAP financial measures used by other companies. Endo assumes no obligation to publicly update any forward looking statement s, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law. Th e forward looking statements in this presentation are qualified by these risk factors. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the Unite d States and Canada including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein or therein, c ould affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in any forward looking statements. Although Endo believes that these forward looking statements and informat ion are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or inf ormation in this news release. Because these statements reflect our current views, expectations and beli efs concerning future events, these forward looking statements involve risks and uncertainties. Similar expressions are forward looking statements. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future projects" or This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislation. Its Generic Pharmaceuticals segment consists of a product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays.Forward Looking Statements Non-GAAP Financial Measures Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. ![]() Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL, EDEX and LIDODERM, among others. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. ![]() The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Health Care : Pharmaceuticals | Small Cap ValueĮndo International plc is a specialty pharmaceutical company. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |